- MeSH
- farmakoterapie metody využití MeSH
- kombinovaná farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů farmakoterapie terapie MeSH
- nádory prsu farmakoterapie komplikace terapie MeSH
- postmenopauza fyziologie účinky léků MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
Targeting and tailoring of therapy is the latest trend in breast cancer treatment. The efficacy of the available treatment must be estimated and the probable benefit for the patient determined. The aim of this project was to find out wether also in postmenopausal women chemotherapy can affect hormonal levels in serum and if even the levels of IGF-1 and IGFBP-3 can be changed. In the group of 72 postmenopausal breast cancer patients blood samples were taken before, during and after adjuvant chemotherapy and levels of estradiol, progesterone, LH, FSH, IGF-1 and IGFBP-3 were evaluated. We did not find any statistically significant dependence on tumor stage, expression of hormonal receptors or HER-2 and treatment regimen with studied hormones. Serum levels before treatment in comparison with status during treatment were significantly different in LH, FSH and progesterone value. Hormone levels after the treatment in comparison with status during treatment were significantly different only in levels of estradiol. Significant differences in all parameters were found except IGF-1. There was not any statistical dependence on the menopausal gap, age, weight or type of chemotherapy. We can conclude, that also in postmenopausal women hormonal changes can take part in the final effect of adjuvant treatment.
- MeSH
- adjuvantní chemoterapie MeSH
- duktální karcinom prsu farmakoterapie metabolismus MeSH
- estradiol metabolismus MeSH
- estrogeny metabolismus MeSH
- financování organizované MeSH
- folikuly stimulující hormon metabolismus MeSH
- insulinu podobný růstový faktor I metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- luteinizační hormon metabolismus MeSH
- nádory prsu farmakoterapie metabolismus MeSH
- postmenopauza MeSH
- progesteron metabolismus MeSH
- protokoly protinádorové kombinované chemoterapie farmakologie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- hodnotící studie MeSH
We explored the relationship between circulating HER-2 extracellular domain and tissue HER-2 status in a group of 42 postmenopausal breast cancer patients. All patients were examined before adjuvant chemotherapy or other adjuvant treatment. Serum levels were measured by BAYER Advia Centaur System, Golden, CO (the cut-off level was in our conditions considered at 12 ng/ml). Tissue expression was assayed with the DAKO HercepTest, North America, Inc, Carpinteria, CA. Our findings that serum levels are in consonance with tissue expression could be important in metastatic breast cancer, when it is impossible to get a new tumour sample and establish the actual HER-2 status, which may be different from the primary tumour. Although we know that serum HER-2 concentration cannot be substituted for IHC or FISH, we have observed a statistically significant correlation between serum level concentration and tissue HER-2 status.
- MeSH
- finanční podpora výzkumu jako téma MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prsu krev metabolismus MeSH
- receptor erbB-2 krev metabolismus MeSH
- receptory pro estrogeny metabolismus MeSH
- receptory progesteronu metabolismus MeSH
- regulace genové exprese u nádorů MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
